Wealthfront Advisers LLC Biomarin Pharmaceutical Inc Transaction History

Wealthfront Advisers LLC

$32.2 Billion
Q3 2024

A detailed history of Wealthfront Advisers LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Wealthfront Advisers LLC holds 30,188 shares of BMRN stock, worth $2.01 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

30,188

Previous 30,807 2.01%

Holding current value

$2.01 Million

Previous $2.54 Million 16.36%

% of portfolio

0.01%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$69.02 - $93.84 $42,723 - $58,086	-619 Reduced 2.01%	30,188 $2.12 Million
Q2 2024 Aug 14, 2024	BUY	$74.43 - $92.22 $269,362 - $333,744	3,619 Added 13.31%	30,807 $2.54 Million
Q1 2024 Apr 19, 2024	SELL	$83.81 - $99.0 $221,928 - $262,152	-2,648 Reduced 8.88%	27,188 $2.37 Million
Q4 2023 Feb 09, 2024	BUY	$76.22 - $98.51 $502,366 - $649,279	6,591 Added 28.35%	29,836 $2.88 Million
Q3 2023 Nov 01, 2023	SELL	$85.07 - $94.48 $490,258 - $544,488	-5,763 Reduced 19.87%	23,245 $2.06 Million
Q2 2023 Aug 07, 2023	SELL	$86.68 - $100.3 $1.33 Million - $1.54 Million	-15,342 Reduced 34.59%	29,008 $2.51 Million
Q1 2023 Apr 28, 2023	BUY	$87.74 - $117.27 $1.87 Million - $2.5 Million	21,347 Added 92.8%	44,350 $4.31 Million
Q4 2022 Feb 10, 2023	BUY	$80.93 - $108.63 $1.35 Million - $1.82 Million	16,727 Added 266.52%	23,003 $2.38 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $297,419 - $350,922	3,620 Added 136.3%	6,276 $532,000
Q2 2022 Jul 20, 2022	BUY	$71.48 - $86.85 $189,850 - $230,673	2,656 New	2,656 $220,000

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wealthfront Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wealthfront Advisers LLC with notifications on news.

Account

Wealthfront Advisers LLC Biomarin Pharmaceutical Inc Transaction History